Sort
15,273 grants matching “antimicrobial resistance”
Developmental and Translational Pharmacology of Pediatric Antimicrobial Therapy
$770,953Edmund Vincent Capparelli · University Of California, San Diego · U54 · FY2011 · HD
Collateral Consequences of Enabler Genotypes in Antibiotic Treatment Failure.
$770,793Jason W. Rosch · Boston Children'S Hospital · U19 · FY2025 · AI
A Scalable Platform to Discover Antimicrobials of Ribosomal Origin
$770,174Huimin Zhao · University Of Illinois At Urbana-Champaign · R01 · FY2023 · AI
A Scalable Platform to Discover Antimicrobials of Ribosomal Origin
$770,174Huimin Zhao · University Of Illinois At Urbana-Champaign · R01 · FY2022 · AI
TOPICAL PROTEGRINS TO PREVENT STDS &HIV INFECTION
$770,122University Of California Los Angeles · P01 · FY2001 · AI
Task A18: Therapeutic Testing in Murine Models of Bacterial Thigh and Lung Infections
$769,825Lynn Miesel · · N01 · FY2018 · AI
The impact of bacteriophage therapy on wound infection dynamics
$769,586Daniel J Wozniak · Ohio State University · R01 · FY2022 · AI
Repurposing Gram-positive Antibiotics for Gram-Negative Bacteria using Antibiotic Adjuvants
$769,579Christian C Melander · University Of Notre Dame · R01 · FY2022 · AI
Excellence in Research: Evaluating Environmental Stressor Effects on Soil Bacterial Traits
$769,173Danielle Graham · Fayetteville State University · · FY2023 · BIO
**AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** ACCORDING TO A USDA ECONOMIC RESEARCH SERVICE REPORT IN 2018, THE ECONOMIC BURDEN DUE TO 15 FOODBORNE PATHOGENS WAS ESTIMATED CLOSE TO $18 BILLION IN THE U.S. SALMONELLA AND CAMPYLOBACTER CAUSED THE MOST REPORTED BACTERIAL FOODBORNE ILLNESSES. EPIDEMIOLOGICAL STUDIES HAVE SUGGESTED THAT PRODUCTS OF POULTRY ORIGIN ARE AMONG THE MOST COMMON VEHICLES FOR TRANSMISSION OF SALMONELLA SPP. AND CAMPYLOBACTER SPP.. IN THE U.S., POULTRY MEAT CONSUMPTION IS INCREASING PER CAPITA PER YEAR COMPARED TO THE REST OF THE WORLD. BACTERIA FROM FARM PRODUCTION, SLAUGHTERHOUSES, AND PROCESSING EQUIPMENT CONTAMINATE CARCASSES AND PROCESSED MEAT PRODUCTS. THE PRESENCE OF VERY LOW LEVELS OF LIVE BACTERIA IN FOOD SAMPLES CAN RENDER THE FOOD HAZARDOUS. MICROBIOLOGICAL CULTURE-BASED METHODS ARE LIMITED IN THEIR ABILITY TO PROVIDE TIMELY DATA. CURRENTLY AVAILABLE RAPID DETECTION SYSTEMS ARE OFTEN LABORIOUS, EXPENSIVE, AND REQUIRE LABORATORY FACILITIES. THEY ALSO LACK THE ABILITY TO QUICKLY ENRICH AND DETECT TARGETS IN LARGE SAMPLES. THERE IS AN UNMET NEED FOR RAPID, LOW-COST, ONSITE, AND ACCURATE DETECTION OF FOODBORNE AGENTS IN LARGE SAMPLES. THUS, THE GOAL OF THIS PROPOSAL IS TO RAPIDLY MONITOR THE TEMPORAL DYNAMICS OF SALMONELLA AND CAMPYLOBACTER INFECTION IN POULTRY FARMS AND SLAUGHTER FACILITIES USING A NANOPARTICLE-BASED BIOSENSOR WITH CAPABILITIES FOR RAPID AND SIMULTANEOUS ENRICHMENT, DETECTION, AND REPORTING OF MULTIPLE AGENTS.THIS RESEARCH IS A PARTNERSHIP BETWEEN MICHIGAN STATE UNIVERSITY AND TUSKEGEE UNIVERSITY FOR FOOD SAFETY. DUE TO ITS SIMPLICITY AND AFFORDABILITY, THE CELLPHONE-ENABLED SMART BIOSENSOR CAN BE USED ONSITE TO MONITOR AND GENERATE INTERNAL INFORMATION ON THE EFFECTIVENESS OF ANTIMICROBIAL INTERVENTION STRATEGIES, PROVIDE TEMPORAL DYNAMICS OF THE INFECTION RATE AT CONTROL POINTS, AND PROVIDE EARLY INFORMATION ON POTENTIAL DEVELOPMENT OF ANTIMICROBIAL RESISTANCE OF THE BACTERIA TO THE TREATMENT AND PREVENTION STRATEGIES.ALTHOUGH THE BIOSENSOR MAY NOT BE ABLE TO REPLACE CULTURE AND MAY NOT BE AS SENSITIVE AS REAL-TIME POLYMERASE CHAIN REACTION (RT-PCR), IT WILL ALLOW HIGH FREQUENCY TESTING AND SUPPORT FASTER DECISION-MAKING BY PRODUCERS AND OPERATORS, RESULTING IN THE IMPLEMENTATION OF PATHOGEN REDUCTION PROGRAMS THAT WILL PREVENT THESE PATHOGENS FROM ENTERING THE FOOD SUPPLY CHAIN, THUS PROTECTING PUBLIC HEALTH, REDUCING FOODBORNE ILLNESS OUTBREAKS, AND SUSTAINING THE AVAILABILITY OF NUTRITIOUS FOODS. THE BIOSENSING TECHNOLOGY WILL ALSO BE ABLE TO GUIDE PRODUCERS IDENTIFY SPECIFIC SITES IN THEIR FACILITIES THAT NEED IMPROVED SANITATION AND INTERVENTION STRATEGIES, RESULTING IN HIGHER EFFICIENCY OF OPERATION, INCREASED PRODUCTIVITY, AND OVERALL HIGHER BUSINESS PROFITABILITY.
$769,000Michigan State University · · FY2022 · National Institute of Food and Agriculture
Mechanisms of Chromosome Maintenance in Bacteria
$768,949Dhruba K Chattoraj · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
VACCINE TREATMENT AND EVALUATION UNIT:CONCEPT AND PROTOCOL DEVELOPMENT
$768,693Clarence Buddy Creech · · N01 · FY2017 · AI
Novel Combination Therapies to Combat Hypermutable Carbapenem-Resistant P. aeruginosa
$768,514Brian Tsuji · State University Of New York At Buffalo · R01 · FY2024 · AI
The clinical and molecular epidemiology of colistin-resistant carbapenem-resistant Enterobacteriaceae (CRE) in long-term acute care hospitals (LTACHs)
$768,456Ebbing Lautenbach · University Of Pennsylvania · R01 · FY2021 · AI
Measuring Intralesional Drug Exposures in Cavitary TB using Noninvasive In Vivo PET Imaging
$768,371Sanjay Jain · Johns Hopkins University · R01 · FY2024 · AI
Community Reservoirs of Extended-Spectrum Beta-Lactamase-producing and Multi-Drug Resistant Enterobacterales
$768,195Latania K. Logan · Emory University · R01 · FY2025 · AI
Project 3 -Translational development of a microneedle patch gonorrhea vaccine (CIIG)
$768,062Emrullah Korkmaz · Henry M. Jackson Fdn For The Adv Mil/Med · U19 · FY2025 · AI
Role of Th17 in Severe and Recurrent C. difficile Infection
$767,972William A Petri · University Of Virginia · R01 · FY2020 · AI
Bacillus subtilis Stress Responses
$767,181John D. Helmann · Cornell University · R35 · FY2018 · GM
Genomics of S. Aureus Colonization after Initial and Recurrent Skin Infections and the Impact of Antibiotics
$766,989Michael Zdenek David · University Of Pennsylvania · R01 · FY2020 · AI
Therapeutic drug monitoring for linezolid in the treatment of rifampin-resistant tuberculosis: a pragmatic randomized controlled trial
$766,877James C M Brust · Albert Einstein College Of Medicine · R01 · FY2025 · AI
Use of De Novo Synthesis Approaches and Structure-guided Design to Optimize Therapeutic Properties of Streptothricin Class Antimicrobials
$766,825James E Kirby · Beth Israel Deaconess Medical Center · R01 · FY2023 · AI
Target-based Assays and Screening Strategies for Chemical Probe and Therapeutic Lead Discovery
$766,601James Inglese · National Center For Advancing Translational Sciences · ZIA · FY2024 · TR
Chemistry Core
$766,342Jeffrey Aube · Weill Medical Coll Of Cornell Univ · U19 · FY2020 · AI
Changing Cultures in Sepsis: Rapid single-cell pathogen identification and antibiotic susceptibility testing directly from whole blood
$766,303Samuel Yang · Stanford University · R01 · FY2020 · AI